Cancer is a very common disease that affects a large population of humans. Cancer is very dangerous due to the fact that it affects various different tissues and cells. This disease also exists in many different forms which makes it hard to deal with. One very rare and dangerous type of cancer is colorectal cancer which can appear in different phases each of different severity.
New research conducted by a team of scientists from the Jefferson (Philadelphia University + Thomas Jefferson University) has just recently published a study that featured on the Journal for ImmunoTherapy of Cancer. The study relating to cancer was focused on finding new treatments for colorectal cancer; especially phase 1. The study has developed a new vaccine that is actually beneficial to treat phase 1 colorectal cancer.
This study was led by Ph.D. holder, Dr. Karen E. Knudsen, who is an EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center — Jefferson Health. She commented on her results saying, “There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type. This is a true milestone– made possible through the scientists and clinicians in our colorectal cancer team working in synchrony.”